Cannabis and Bipolar Disorder
What the evidence actually says about using cannabis for mania, depression, and mood stability in bipolar disorder.
Bipolar disorder and cannabis is one of the most uncomfortable topics in cannabis medicine. People with bipolar disorder use cannabis at roughly two to three times the rate of the general population, and many report it helps. The controlled research, however, consistently shows worse outcomes: more manic episodes, faster cycling, worse adherence to medication, and higher psychosis risk. There is no good evidence that cannabis treats bipolar disorder, and meaningful evidence that heavy use makes it worse. CBD-only products are less studied and probably less risky, but still not proven.
Not Medical Advice
This article is not medical advice. Bipolar disorder is a serious psychiatric condition that can be life-threatening if untreated. Do not start, stop, or change any medication based on what you read here. If you have bipolar disorder, decisions about cannabis use should involve your prescribing clinician. If you are in crisis, contact emergency services or a crisis line (in the US, call or text 988).
Plain-Language Summary
Bipolar disorder is a mood disorder defined by episodes of mania (or hypomania) and, in most patients, episodes of depression. Standard treatment is medication — lithium, valproate, lamotrigine, atypical antipsychotics — usually combined with psychotherapy and sleep regulation [1].
People with bipolar disorder use cannabis at much higher rates than the general population. Estimates from large epidemiological samples put lifetime cannabis use disorder in bipolar I patients somewhere between 20% and 30%, compared to roughly 6–8% in the general adult population [2][3]. Many users say cannabis helps them sleep, calms racing thoughts, or eases depression.
The research picture is much less friendly. Across multiple longitudinal studies, cannabis use in bipolar patients is associated with earlier onset of illness, more frequent manic episodes, faster cycling, more hospitalizations, and worse medication adherence [3][4][5]. There are no randomized controlled trials showing that whole-plant cannabis or THC improves any phase of bipolar disorder. CBD has been studied for psychosis and anxiety, but evidence in bipolar disorder specifically is thin.
What Probably Works
Nothing, on current evidence. There is no cannabis-based intervention — whole flower, THC, CBD, or combined preparations — that has been shown in adequately powered randomized trials to treat bipolar mania, bipolar depression, or to prevent recurrence No data.
This is a real gap, not just an absence of attention. The trials that exist are small, short, and mostly negative or inconclusive. Until that changes, 'probably works' is empty for this condition.
What Might Work (Weak or Preliminary Evidence)
CBD as an adjunct. CBD has shown antipsychotic and anxiolytic effects in schizophrenia and anxiety disorders in small trials [6][7]. By extrapolation, some clinicians have wondered whether CBD might help bipolar patients with anxiety or psychotic features. A 2020 open-label pilot in 35 patients with bipolar depression found CBD 150–300 mg/day was well tolerated but did not separate from placebo on depression measures [8] Weak / limited. This is hypothesis-generating, not evidence of benefit.
Sleep and anxiety symptom relief. Many bipolar patients report short-term subjective relief of insomnia or anxiety from cannabis Anecdote. Self-report studies confirm this is a common reason for use [9]. However, subjective relief is not the same as improvement in illness course, and the same studies find these users have worse long-term outcomes.
Cannabidiol with low-dose THC for agitation. There is interest in CBD-dominant formulations for agitation in dementia and autism. None of this has been replicated in bipolar disorder No data.
What Doesn't Work or Has Weak Evidence
THC-dominant cannabis for mania. Multiple cohort studies show cannabis use precedes and predicts manic episodes, including in patients who were previously stable [4][5] Strong evidence. THC's pro-dopaminergic and pro-psychotic effects are biologically consistent with this signal.
Cannabis as a 'natural mood stabilizer.' This is online folklore. No controlled trial supports it, and the longitudinal data point the other way [evidence:strong against].
'Indica strains for bipolar depression.' The indica/sativa distinction does not reliably predict pharmacological effects [10]. Choosing a chemovar by its marketing label is not a treatment strategy No data.
What We Don't Know
- Whether pure CBD at therapeutic doses (300–800 mg/day, as used in epilepsy and psychosis trials) has any role as an adjunct to mood stabilizers. Pilot data are inconclusive [8].
- Whether the association between cannabis and worse bipolar course is fully causal, partly reverse causation (sicker patients self-medicate more), or driven by shared genetic risk. The best longitudinal evidence supports a causal contribution but cannot rule out confounding entirely [4][5] [evidence:disputed on mechanism, not on association].
- Whether there is a dose threshold below which cannabis is neutral rather than harmful for bipolar patients.
- Whether CBD's known interactions with mood stabilizers — particularly valproate (hepatotoxicity risk) and clobazam — translate into clinically meaningful problems with lamotrigine, lithium, or quetiapine at common consumer CBD doses [11].
Comparison with Standard Treatments
Standard pharmacological treatments for bipolar disorder have decades of randomized evidence:
- Lithium remains the best-evidenced mood stabilizer, reduces suicide risk, and is first-line for bipolar I [1][12] Strong evidence.
- Valproate is effective for acute mania Strong evidence; contraindicated in pregnancy.
- Lamotrigine is effective for prevention of bipolar depression Strong evidence.
- Quetiapine, olanzapine, lurasidone, cariprazine have RCT support for various phases [1] Strong evidence.
- Psychotherapy (CBT, family-focused therapy, IPSRT) reduces relapse Strong evidence.
Cannabis has no comparable evidence base for any phase of bipolar disorder. Using it in place of these treatments is not supported.
Risks
Mania and psychosis. THC can precipitate manic and psychotic episodes, especially with high-potency products and in younger users [4][13] Strong evidence. In bipolar patients, this risk is amplified.
Faster cycling and more hospitalizations. Prospective cohorts show cannabis-using bipolar patients have more frequent and more severe episodes than non-users with the same diagnosis [3][5] Strong evidence.
Medication non-adherence. Cannabis use disorder is associated with poorer adherence to mood stabilizers, which is itself the strongest predictor of relapse [3] Strong evidence.
Drug interactions. CBD inhibits several CYP450 enzymes (notably CYP2C19, CYP3A4, CYP2C9) and can raise levels of valproate (with documented hepatotoxicity in epilepsy trials), clobazam, and potentially other psychiatric drugs [11] Strong evidence.
Cannabis use disorder. Bipolar patients are at substantially elevated risk of developing CUD compared to the general population [2] Strong evidence.
Suicide risk. Cannabis use in bipolar disorder is associated with increased suicidal behavior in several cohorts [14] Strong evidence.
Bottom Line
Cannabis is not a treatment for bipolar disorder. People with bipolar disorder who use cannabis tend to do worse over time, even when they feel better in the short term. CBD-only products are less risky than THC-dominant cannabis but are not proven helpful and have real interactions with mood stabilizers. If you have bipolar disorder and use cannabis, the most useful thing this article can tell you is: talk to your psychiatrist about it honestly, and do not stop your mood stabilizer.
Sources
- Peer-reviewed Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders. 2018;20(2):97-170.
- Peer-reviewed Hunt GE, Malhi GS, Cleary M, Lai HM, Sitharthan T. Comorbidity of bipolar and substance use disorders in national surveys of general populations, 1990-2015: Systematic review and meta-analysis. Journal of Affective Disorders. 2016;206:321-330.
- Peer-reviewed Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J. Bipolar disorder and co-occurring cannabis use disorders: characteristics, co-morbidities and clinical correlates. Psychiatry Research. 2013;209(3):459-465.
- Peer-reviewed Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J. Cannabis use and expression of mania in the general population. Journal of Affective Disorders. 2006;95(1-3):103-110.
- Peer-reviewed Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP. Cannabis use and mania symptoms: a systematic review and meta-analysis. Journal of Affective Disorders. 2015;171:39-47.
- Peer-reviewed McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. American Journal of Psychiatry. 2018;175(3):225-231.
- Peer-reviewed Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-1226.
- Peer-reviewed Pinto JV, Crippa JAS, Ceresér KM, et al. Cannabidiol as an adjunctive treatment for acute bipolar depression: a pilot study. Canadian Journal of Psychiatry. 2020;65(7):505-507.
- Peer-reviewed Ashton CH, Moore PB, Gallagher P, Young AH. Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. Journal of Psychopharmacology. 2005;19(3):293-300.
- Peer-reviewed Smith CJ, Vergara D, Keegan B, Jikomes N. The phytochemical diversity of commercial Cannabis in the United States. PLoS ONE. 2022;17(5):e0267498.
- Peer-reviewed Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine. 2019;8(7):989.
- Peer-reviewed Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.
- Peer-reviewed Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427-436.
- Peer-reviewed Østergaard MLD, Nordentoft M, Hjorthøj C. Associations between substance use disorders and suicide or suicide attempts in people with mental illness: a Danish nation-wide, prospective, register-based study. Addiction. 2017;112(7):1250-1259.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Depression — What the evidence actually says about using cannabis for depressive disorders, separating...
- Cannabis and Schizophrenia — What the evidence actually says about cannabis as a risk factor, trigger, and potential tr...
- Cannabis-Induced Psychosis — What we actually know about cannabis triggering psychotic symptoms, who's at risk, and how...